RT Journal Article
SR Electronic
T1 Neoadjuvant Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3301
OP 3306
VO 37
IS 6
A1 KAWAI, TAKAHARU
A1 KOCHI, MITSUGU
A1 FUJII, MASASHI
A1 SONG, KEIO
A1 HAGIWARA, KEN
A1 WATANABE, MEGUMU
A1 MATSUNO, YORITAKA
A1 SUDA, HIROSHI
A1 YAGI, RENPEI
A1 TAKAYAMA, TADATOSHI
YR 2017
UL http://ar.iiarjournals.org/content/37/6/3301.abstract
AB Background/Aim: The goal of this retrospective study was to investigate the efficacy and safety of neoadjuvant chemoradiotherapy (CRT) in patients with Stage II or Stage III esophageal squamous cell carcinoma (SCC). Patients and Methods: Between January 2004 and December 2014, a total of 86 patients underwent surgical resection in conjunction with preoperative CRT for esophageal SCC in our Institute. Results: A pathological complete response was achieved in 38.7% of patients with Stage II cancer and 20% of patients with Stage III. Postoperative complications were observed in 61.3% of Stage II and 76.4% of Stage III patients. The 5-year overall survival rate (OS) was 83.2% in Stage II and 22.8% in Stage III (p=0.0001). The 5-year disease-free survival (DFS) rate was 67.9% in Stage II and 29.9% in Stage III (p=0.0007). Conclusion: Neoadjuvant CRT may improve OS and DFS rates in patients with Stage II esophageal SCC.